Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.

McCarthy JS, Lotharius J, Rückle T, Chalon S, Phillips MA, Elliott S, Sekuloski S, Griffin P, Ng CL, Fidock DA, Marquart L, Williams NS, Gobeau N, Bebrevska L, Rosario M, Marsh K, Möhrle JJ.

Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.

2.

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.

Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, Rathod PK, Burrows JN, Charman SA.

Sci Transl Med. 2015 Jul 15;7(296):296ra111. doi: 10.1126/scitranslmed.aaa6645.

3.

Repositioning: the fast track to new anti-malarial medicines?

Lotharius J, Gamo-Benito FJ, Angulo-Barturen I, Clark J, Connelly M, Ferrer-Bazaga S, Parkinson T, Viswanath P, Bandodkar B, Rautela N, Bharath S, Duffy S, Avery VM, Möhrle JJ, Guy RK, Wells T.

Malar J. 2014 Apr 14;13:143. doi: 10.1186/1475-2875-13-143.

4.

In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models.

Schleiferböck S, Scheurer C, Ihara M, Itoh I, Bathurst I, Burrows JN, Fantauzzi P, Lotharius J, Charman SA, Morizzi J, Shackleford DM, White KL, Brun R, Wittlin S.

Drug Des Devel Ther. 2013 Nov 15;7:1377-84. doi: 10.2147/DDDT.S51298. eCollection 2013.

5.

In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species.

Wittlin S, Ekland E, Craft JC, Lotharius J, Bathurst I, Fidock DA, Fernandes P.

Antimicrob Agents Chemother. 2012 Feb;56(2):703-7. doi: 10.1128/AAC.05039-11. Epub 2011 Nov 14.

6.

Challenges in antimalarial drug discovery.

Burrows JN, Leroy D, Lotharius J, Waterson D.

Future Med Chem. 2011 Sep;3(11):1401-12. doi: 10.4155/fmc.11.91. Review.

PMID:
21879844
7.

A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons.

Tansley R, Lotharius J, Priestley A, Bull F, Duparc S, Möhrle J.

Am J Trop Med Hyg. 2010 Dec;83(6):1195-201. doi: 10.4269/ajtmh.2010.10-0228.

8.

HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells.

Johansen JL, Sager TN, Lotharius J, Witten L, Mørk A, Egebjerg J, Thirstrup K.

J Neurochem. 2010 Oct;115(1):209-19. doi: 10.1111/j.1471-4159.2010.06917.x. Epub 2010 Aug 19.

9.

Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells.

Schildknecht S, Pöltl D, Nagel DM, Matt F, Scholz D, Lotharius J, Schmieg N, Salvo-Vargas A, Leist M.

Toxicol Appl Pharmacol. 2009 Nov 15;241(1):23-35. doi: 10.1016/j.taap.2009.07.027. Epub 2009 Jul 30.

PMID:
19647008
10.

Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.

Vergo S, Johansen JL, Leist M, Lotharius J.

Brain Res. 2007 Dec 14;1185:18-32. Epub 2007 Sep 21.

PMID:
18028884
11.

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.

Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J.

Br J Pharmacol. 2007 Nov;152(6):959-79. Epub 2007 Oct 1.

12.

Inflammation in Parkinson's disease: causative or epiphenomenal?

Hald A, Van Beek J, Lotharius J.

Subcell Biochem. 2007;42:249-79. Review.

PMID:
17612055
13.
14.

Oxidative stress and inflammation in Parkinson's disease: is there a causal link?

Hald A, Lotharius J.

Exp Neurol. 2005 Jun;193(2):279-90. Review.

PMID:
15869932
15.

Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347.

Falsig J, Pörzgen P, Lotharius J, Leist M.

J Immunol. 2004 Aug 15;173(4):2762-70.

16.

Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons.

O'Malley KL, Liu J, Lotharius J, Holtz W.

Neurobiol Dis. 2003 Oct;14(1):43-51.

PMID:
13678665
17.

[Free radicals and ailing proteins--the culprits behind Parkinson disease?].

Smith R, Lotharius J, Brundin P.

Lakartidningen. 2003 Apr 10;100(15):1324-6, 1329-30. Review. Swedish.

PMID:
12739402
18.

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.

Lotharius J, Brundin P.

Nat Rev Neurosci. 2002 Dec;3(12):932-42. Review. No abstract available.

PMID:
12461550
19.

Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.

Petersén A, Puschban Z, Lotharius J, NicNiocaill B, Wiekop P, O'Connor WT, Brundin P.

Neurobiol Dis. 2002 Oct;11(1):134-46.

PMID:
12460553
20.
21.

Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.

Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P.

J Biol Chem. 2002 Oct 11;277(41):38884-94. Epub 2002 Jul 26.

22.

Fullerene-based antioxidants and neurodegenerative disorders.

Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL.

Parkinsonism Relat Disord. 2001 Jul;7(3):243-246.

PMID:
11331193
23.
25.

Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons.

Lotharius J, Dugan LL, O'Malley KL.

J Neurosci. 1999 Feb 15;19(4):1284-93.

26.

hMO or FMC? Drastic changes ahead in medical care.

Lotharius J.

IMJ Ill Med J. 1971 Jan;139(1):50-2. No abstract available.

PMID:
4395950

Supplemental Content

Loading ...
Support Center